Patents by Inventor Christi L. Wood

Christi L. Wood has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies specifically binding to MASP-3 for the treatment of various diseases and disorders
    Patent number: 11883493
    Abstract: The present invention relates to MASP-3 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-3 dependent complement activation.
    Type: Grant
    Filed: April 27, 2021
    Date of Patent: January 30, 2024
    Assignee: OMEROS CORPORATION
    Inventors: W. Jason Cummings, Gregory A. Demopulos, Thomas Dudler, Larry W. Tjoelker, Christi L. Wood, Munehisa Yabuki
  • COMPOSITION AND METHODS OF TARGETING THE PRE-B CELL RECEPTOR FOR THE TREATMENT OF LEUKEMIAS AND LYMPHOMAS
    Publication number: 20220265821
    Abstract: The present invention relates to antibodies that bind the pre-B cell receptor components VpreB and lambda-5, and compositions comprising such antibodies for use in diagnosing and eliminating pre-BCR-expressing leukemia and lymphoma cells. In one aspect, the present invention provides isolated antibodies or an antigen-binding fragment thereof capable of specifically binding to a SLC. The SLC is composed of two noncovalently-linked polypeptides, VpreB and lambda-5.
    Type: Application
    Filed: July 17, 2020
    Publication date: August 25, 2022
    Inventors: Patrick W. GRAY, Larry W. TJOELKER, Christi L. WOOD
  • ANTIBODIES SPECIFICALLY BINDING TO MASP-3 FOR THE TREATMENT OF VARIOUS DISEASES AND DISORDERS
    Publication number: 20210275667
    Abstract: The present invention relates to MASP-3 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-3 dependent complement activation.
    Type: Application
    Filed: April 27, 2021
    Publication date: September 9, 2021
    Inventors: W. Jason Cummings, Gregory A. Demopulos, Thomas Dudler, Larry W. Tjoelker, Christi L. Wood, Munehisa Yabuki
  • Antibodies specifically binding to MASP-3 for the treatment of various diseases and disorders
    Patent number: 11027015
    Abstract: The present invention relates to MASP-3 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-3 dependent complement activation.
    Type: Grant
    Filed: June 23, 2020
    Date of Patent: June 8, 2021
    Assignee: Omeros Corporation
    Inventors: W. Jason Cummings, Gregory A. Demopulos, Thomas Dudler, Larry W. Tjoelker, Christi L. Wood, Munehisa Yabuki
  • ANTIBODIES SPECIFICALLY BINDING TO MASP-3 FOR THE TREATMENT OF VARIOUS DISEASES AND DISORDERS
    Publication number: 20200317510
    Abstract: The present invention relates to MASP-3 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-3 dependent complement activation.
    Type: Application
    Filed: June 23, 2020
    Publication date: October 8, 2020
    Inventors: W. Jason Cummings, Gregory A. Demopulos, Thomas Dudler, Larry W. Tjoelker, Christi L. Wood, Munehisa Yabuki
  • NUCLEIC ACIDS ENCODING ANTIBODIES SPECIFICALLY BINDING TO MASP-3
    Publication number: 20200270125
    Abstract: The present invention relates to MASP-3 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-3 dependent complement activation.
    Type: Application
    Filed: April 1, 2020
    Publication date: August 27, 2020
    Inventors: W. Jason Cummings, Gregory A. Demopulos, Thomas Dudler, Larry W. Tjoelker, Christi L. Wood, Munehisa Yabuki
  • Nucleic acids encoding antibodies specifically binding to MASP-3
    Patent number: 10745274
    Abstract: The present invention relates to MASP-3 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-3 dependent complement activation.
    Type: Grant
    Filed: April 1, 2020
    Date of Patent: August 18, 2020
    Assignee: Omeros Corporation
    Inventors: W. Jason Cummings, Gregory A. Demopulos, Thomas Dudler, Larry W. Tjoelker, Christi L. Wood, Munehisa Yabuki
  • Antibodies specifically binding to MASP-3 for the treatment of various diseases and disorders
    Patent number: 10639369
    Abstract: The present invention relates to MASP-3 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-3 dependent complement activation.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: May 5, 2020
    Assignee: Omeros Corporation
    Inventors: W. Jason Cummings, Gregory A. Demopulos, Thomas Dudler, Larry W. Tjoelker, Christi L. Wood, Munehisa Yabuki
  • Compositions and Methods of Inhibiting MASP-3 for the Treatment of Various Diseases and Disorders
    Publication number: 20180140697
    Abstract: The present invention relates to MASP-3 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-3 dependent complement activation.
    Type: Application
    Filed: July 31, 2017
    Publication date: May 24, 2018
    Inventors: W. Jason Cummings, Gregory A. Demopulos, Thomas Dudler, Hans-Wilhelm Schwaeble, Larry W. Tjoelker, Christi L. Wood, Munehisa Yabuki
  • Anti-FZD10 monoclonal antibodies and methods for their use
    Patent number: 9777065
    Abstract: The present invention relates generally to anti-FZD10 antibodies and to methods of using anti-FZD10 antibodies. In particular, the anti-FZD10 antibodies described herein are useful for altering one or more of survival, replication, differentiation and epithelial-to-mesenchymal cell transition of embryonic stem cells and/or for the treatment of diseases, such as a variety of cancers, associated with expression of FZD10, including as stand-alone therapies and in combination therapies with other agents.
    Type: Grant
    Filed: July 1, 2015
    Date of Patent: October 3, 2017
    Assignee: Omeros Corporation
    Inventors: W. Jason Cummings, Munehisa Yabuki, John B. Leppard, Christi L. Wood, Nancy Maizels, Daniel S. Allison, Larry W. Tjoelker
  • Composition and method for diversification of target sequences
    Patent number: 9677070
    Abstract: The disclosure relates generally to the targeting of genes to, and their integration into, an immunoglobulin (antibody) heavy chain locus. In particular, the methods described herein contemplate replacing the single rearranged heavy chain V, D, and J genes of a B cell lymphoma such as DT40 with independently rearranged VH-D-JH genes of chicken, in a system for generating immunoglobulin diversity. Also contemplated is replacement of the chicken VH-D-JH with rearranged VH-D-JH genes of other vertebrates including human in a system for generating immunoglobulin diversity, with the exception of any substitution disclosed and claimed in PCT application WO 2009/029315 A2. Also described is construction of a diverse chicken immunoglobulin heavy chain VDJ library in DT40 by homologous gene replacement of the single endogenous rearranged VDJ gene with a chicken VDJ repertoire using the described targeting vectors.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: June 13, 2017
    Assignees: Omeros Corporation, University of Washington Through Its Center for Commercialization
    Inventors: Daniel S. Allison, W. Jason Cummings, John B. Leppard, Nancy Maizels, Larry W. Tjoelker, Christi L. Wood, Munehisa Yabuki
  • ANTI-FZD10 MONOCLONAL ANTIBODIES AND METHODS FOR THEIR USE
    Publication number: 20160333107
    Abstract: The present invention relates generally to anti-FZD10 antibodies and to methods of using anti-FZD10 antibodies. In particular, the anti-FZD10 antibodies described herein are useful for altering one or more of survival, replication, differentiation and epithelial-to-mesenchymal cell transition of embryonic stem cells and/or for the treatment of diseases, such as a variety of cancers, associated with expression of FZD10, including as stand-alone therapies and in combination therapies with other agents.
    Type: Application
    Filed: July 1, 2015
    Publication date: November 17, 2016
    Inventors: W. Jason Cummings, Munehisa Yabuki, John B. Leppard, Christi L. Wood, Nancy Maizels, Daniel S. Allison, Larry W. Tjoelker
  • Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution
    Patent number: 9346888
    Abstract: The present invention relates generally to anti-FN14 antibodies. In particular, the anti-FN14 antibodies described herein are useful for the treatment of diseases, such as a variety of cancers, associated with expression of FN14.
    Type: Grant
    Filed: November 14, 2013
    Date of Patent: May 24, 2016
    Assignee: Omeros Corporation
    Inventors: John Benjamin Leppard, Christi L. Wood, W. Jason Cummings, Munehisa Yabuki, Nancy Maizels, Daniel S. Allison, Larry W. Tjoelker
  • Anti-FZD10 monoclonal antibodies and methods for their use
    Patent number: 9102724
    Abstract: The present invention relates generally to anti-FZD10 antibodies and to methods of using anti-FZD10 antibodies. In particular, the anti-FZD10 antibodies described herein are useful for altering one or more of survival, replication, differentiation and epithelial-to-mesenchymal cell transition of embryonic stem cells and/or for the treatment of diseases, such as a variety of cancers, associated with expression of FZD10, including as stand-alone therapies and in combination therapies with other agents.
    Type: Grant
    Filed: August 9, 2012
    Date of Patent: August 11, 2015
    Assignee: Omeros Corporation
    Inventors: W. Jason Cummings, Munehisa Yabuki, John B. Leppard, Christi L. Wood, Nancy Maizels, Daniel S. Allison, Larry W. Tjoelker
  • Generation of Anti-FN14 Monoclonal Antibodies by Ex-Vivo Accelerated Antibody Evolution
    Publication number: 20140178385
    Abstract: The present invention relates generally to anti-FN14 antibodies. In particular, the anti-FN14 antibodies described herein are useful for the treatment of diseases, such as a variety of cancers, associated with expression of FN14.
    Type: Application
    Filed: November 14, 2013
    Publication date: June 26, 2014
    Applicant: Omeros Corporation
    Inventors: John Benjamin Leppard, Christi L. Wood, W. Jason Cummings, Munehisa Yabuki, Nancy Maizels, Daniel S. Allison, Larry W. Tjoelker
  • Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution
    Patent number: 8609818
    Abstract: The present invention relates generally to anti-FN14 antibodies. In particular, the anti-FN14 antibodies described herein are useful for the treatment of diseases, such as a variety of cancers, associated with expression of FN14.
    Type: Grant
    Filed: March 9, 2012
    Date of Patent: December 17, 2013
    Assignee: Omeros Corporation
    Inventors: John Benjamin Leppard, Christi L Wood, W Jason Cummings, Munehisa Yabuki, Nancy Maizels, Daniel S Allison, Larry W Tjoelker
  • COMPOSITION AND METHOD FOR DIVERSIFICATION OF TARGET SEQUENCES
    Publication number: 20130261012
    Abstract: The disclosure relates generally to the targeting of genes to, and their integration into, an immunoglobulin (antibody) heavy chain locus. In particular, the methods described herein contemplate replacing the single rearranged heavy chain V, D, and J genes of a B cell lymphoma such as DT40 with independently rearranged VH-D-JH genes of chicken, in a system for generating immunoglobulin diversity. Also contemplated is replacement of the chicken VH-D-JH with rearranged VH-D-JH genes of other vertebrates including human in a system for generating immunoglobulin diversity, with the exception of any substitution disclosed and claimed in PCT application WO 2009/029315 A2. Also described is construction of a diverse chicken immunoglobulin heavy chain VDJ library in DT40 by homologous gene replacement of the single endogenous rearranged VDJ gene with a chicken VDJ repertoire using the described targeting vectors.
    Type: Application
    Filed: March 13, 2013
    Publication date: October 3, 2013
    Applicants: University of Washington Through Its Center for Commercialization, OMEROS CORPORATION
    Inventors: Daniel S. Allison, W. Jason Cummings, John B. Leppard, Nancy Maizels, Larry W. Tjoelker, Christi L. Wood, Munehisa Yabuki
  • ANTI-FZD10 MONOCLONAL ANTIBODIES AND METHODS FOR THEIR USE
    Publication number: 20130095104
    Abstract: The present invention relates generally to anti-FZD10 antibodies and to methods of using anti-FZD10 antibodies. In particular, the anti-FZD10 antibodies described herein are useful for altering one or more of survival, replication, differentiation and epithelial-to-mesenchymal cell transition of embryonic stem cells and/or for the treatment of diseases, such as a variety of cancers, associated with expression of FZD10, including as stand-alone therapies and in combination therapies with other agents.
    Type: Application
    Filed: August 9, 2012
    Publication date: April 18, 2013
    Inventors: W. Jason Cummings, Munehisa Yabuki, John B. Leppard, Christi L. Wood, Nancy Maizels, Daniel S. Allison, Larry W. Tjoelker
  • GENERATION OF ANTI-FN14 MONOCLONAL ANTIBODIES BY EX-VIVO ACCELERATED ANTIBODY EVOLUTION
    Publication number: 20120258121
    Abstract: The present invention relates generally to anti-FN14 antibodies. In particular, the anti-FN14 antibodies described herein are useful for the treatment of diseases, such as a variety of cancers, associated with expression of FN14.
    Type: Application
    Filed: March 9, 2012
    Publication date: October 11, 2012
    Applicant: Omeros Corporation
    Inventors: John Benjamin Leppard, Christi L. Wood, W. Jason Cummings, Munehisa Yabuki, Nancy Maizels, Daniel S. Allison, Larry W. Tjoelker